Singapore based company Neuome Peptides Pte Ltd, a start-up backed by
Mercatus Capital Singapore has developed a Peptide-based rapid antigen test
kit, TruCov-Flow. This technology detects SARS-CoV-2 virus from saliva thus
removing the need for swab and results come within 3-5 minutes maximum. It
is ICMR validated and approved as a Novel Product ready for commercial launch
in India which efficiently reduces the time taken in producing the diagnostic
results without cross reactivity.

While talking to Medgate Today, Dr Rajanikanth, Director, Neuome Peptides Pte
Ltd, Singapore, expressed his sincere gratitude to ICMR for approval of
economic, efficient and easy to administer his TruCoV-Flow, Ultra -Sensitive
Covid-19 Saliva based Rapid Antigen Test kit. This new diagnostics kit for all covid
variants scored high on all key ICMR validation parameters like Sensitivity,
Specificity Positive Predictive Value and Negative Predictive Value has been
validated at Laboratory Medicine and Molecular Diagnostics (LMMD), Rajiv
Gandhi Centre for Biotechnology, Thiruvananthapuram, under quality system
procedure of NABL ISO 15189-2012 strictly adhering to ICMR protocols. This
Rapid antigen test kits with expiry time of two years from date of production,
will be commercially produced by ImmunoScience Pvt Ltd in India and nationally
and globally marketed by Neuome Peptides Pte Ltd, Singapore.